Abstract
To evaluate the clinical performance of noninvasive prenatal screening (NIPS) for fetal sex chromosome aneuploidies (SCAs), pregnant women were recruited in this retrospective observational study. The NIPS test was undertaken using high-throughput gene sequencing. In total,50,301 pregnant women were analysed for demographic characteristics and medical history. Of them, 308 women (0.61%) had high risk for fetal SCAs, including 138 for 45,X, 111 for 47,XXY, 42 for 47,XXX, and 17 for 47,XYY. After the pre-test counselling, 182 participants chose to undergo invasive prenatal diagnosis, confirming 59 positive cases. The combined positive predictive value of NIPS was 32.42% (59/182), 18.39% (16/87), 44.4% (12/27), 39.29% (22/56), and 75% (9/12) for detecting SCAs, 45,X, 47,XXX, 47,XXY, and 47,XYY, respectively. NIPS can be a useful method to detect the fetal SCAs using high-throughput gene sequencing, though accuracy can still be improved, especially for 45,X. Although the value of NIPS compare favorably with those seen in traditional screening approaches for SCAs, it is important to highlight the limitations of NIPS while educating clinicians and patients.
Highlights
Birth defects or congenital anomalies refer to anomalies in the anatomy and function of an embryo or fetus during its development due to genetic factors, including chromosomal and genetic anomalies
Noninvasive prenatal screening based on massively parallel genomic sequencing (MPS) technology has been widely applied for the clinical detection of trisomy 21, trisomy 18, and trisomy 139
This study aims to evaluate the clinical performance of non-invasive prenatal screening (NIPS) for detecting fetal sex chromosome aneuploidies (SCAs) using MPS
Summary
Birth defects or congenital anomalies refer to anomalies in the anatomy and function of an embryo or fetus during its development due to genetic factors, including chromosomal and genetic anomalies. The combined frequency of these disorders ranges from 1/500 to 1/850 for male and female fetuses, respectively[2,3] This relatively high incidence makes prenatal screening and diagnosis of SCA’s an attractive option for pregnant women. The detection rate is 75% for trisomy 21 and the false positive rate is 5% with the routine biochemical prenatal screening program[7] This method is not suitable to screen for SCAs. Lo et al.[8] detected the presence of circulating cell free fetal DNA (cffDNA) in the blood samples of pregnant women using sensitive Y-PCR. Lo et al.[8] detected the presence of circulating cell free fetal DNA (cffDNA) in the blood samples of pregnant women using sensitive Y-PCR This discovery opened a new chapter in non-invasive prenatal screening (NIPS), known as noninvasive prenatal testing (NIPT). This study aims to evaluate the clinical performance of NIPS for detecting fetal SCAs using MPS
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.